Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents

Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91 Hotamisligil GS, Arner P, Caro JF et al (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415 Kern PA, Saghizadeh M, Ong JM et al (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111–2119 Pincelli AI, Brunani A, Scacchi M et al (2001) The serum concentration of tumor necrosis factor alpha is not an index of growth-hormone- or obesity-induced insulin resistance. Horm Res 55:57–64 Ronnemaa T, Pulkki K, Kaprio J (2000) Serum soluble tumor necrosis factor-alpha receptor 2 is elevated in obesity but is not related to insulin sensitivity: a study in identical twins discordant for obesity. J Clin Endocrinol Metab 85:2728–2732 Mohamed-Ali V, Goodrick S, Rawesh A et al (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200 Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847–850 Vgontzas AN, Papanicolaou DA, Bixler EO et al (1997) Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 82:1313–1316 Roytblat L, Rachinsky M, Fisher A et al (2000) Raised interleukin-6 levels in obese patients. Obes Res 8:673–675 Bastard JP, Jardel C, Bruckert E et al (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338–3342 Meier CA, Bobbioni E, Gabay C et al (2002) IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87:1184–1188 Juge-Aubry CE, Somm E, Giusti V et al (2003) Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52:1104–1110 Arend WP (1990) Interleukin-1 receptor antagonist: discovery, structure and properties. Prog Growth Factor Res 2:193–205 Neumann D, Kollewe C, Martin MU et al (2000) The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol 165:3350–3357 Luheshi GN, Gardner JD, Rushforth DA et al (1999) Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci USA 96:7047–7052 Gregoire F, De Broux N, Hauser N et al (1992) Interferon-gamma and interleukin-1 beta inhibit adipoconversion in cultured rodent preadipocytes. J Cell Physiol 151:300–309 Suzawa M, Takada I, Yanagisawa J et al (2003) Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 5:224–230 Matsuki T, Horai R, Sudo K et al (2003) IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 198:877–888 Nicklin MJ, Hughes DE, Barton JL et al (2000) Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 191:303–312 Meda P, Bosco D, Chanson M et al (1990) Rapid and reversible secretion changes during uncoupling of rat insulin-producing cells. J Clin Invest 86:759–768 Charollais A, Gjinovci A, Huarte J et al (2000) Junctional communication of pancreatic beta cells contributes to the control of insulin secretion and glucose tolerance. J Clin Invest 106:235–243 Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B (1986) Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats. Endocrinology 118:674–678 Cusin I, Terrettaz J, Rohner-Jeanrenaud F et al (1990) Metabolic consequences of hyperinsulinaemia imposed on normal rats on glucose handling by white adipose tissue, muscles and liver. Biochem J 267:99–103 Vettor R, Zarjevski N, Cusin I et al (1994) Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 37:1202–1208 Herbert V, Lau KS, Gottlieb CW et al (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25:1375–1384 Del Rey A, Besedovsky H (1987) Interleukin 1 affects glucose homeostasis. Am J Physiol 253:R794–R798 Del Rey A, Monge-Arditi G, Besedovsky HO (1998) Central and peripheral mechanisms contribute to the hypoglycemia induced by interleukin-1. Ann N Y Acad Sci 840:153–161 Harkins JM, Moustaid-Moussa N, Chung YJ et al (2004) Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice. J Nutr 134:2673–2677 Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–860 Jhala U, Baly DL (1994) Effect of chronic IL-1 beta infusion on glucose homeostasis and pancreatic insulin secretion. Life Sci 54:413–422 Besedovsky HO, del Rey A (1989) Interleukin-1 and glucose homeostasis: an example of the biological relevance of immune-neuroendocrine interactions. Horm Res 31:94–99 Del Rey A, Besedovsky H (1989) Antidiabetic effects of interleukin 1. Proc Natl Acad Sci USA 86:5943–5947 Lang CH, Dobrescu C (1989) Interleukin-1 induced increases in glucose utilization are insulin mediated. Life Sci 45:2127–2134